Mandate

Vinge has advised CELLINK in a directed issue of new shares

Vinge has advised CELLINK AB (publ) in connection with a directed issue of new shares which will generate approximately MSEK 377 for CELLINK.

The subscription price was determined through an accelerated book‑building and corresponds to a discount of 3.4 per cent compared with the volume‑weighted average listed price during January on Nasdaq First North Growth Market. In addition to considerable support from existing shareholders, several new Swedish and institutional shareholders subscribed for the new issue of shares. An amount of MSEK 150 from the proceeds in relation to the new issue of shares will be used to finance the company’s organic growth plan, future operating capital requirements, etc. and the remaining proceeds can be used to finance strategic acquisitions.

Vinge’s team consisted of Anders StridEdin Agic and Anna Ståhlklo.

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025